Erica Alfonsa Kardenas
Payments from drug & device makers
Across 281 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$761
- Pfizer$683
- Johnson & Johnson$355
- AstraZeneca$234
- GSK$227
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,311100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 66 | $1,167 |
| Novo Nordisk | 33 | $761 |
| Pfizer | 42 | $683 |
| Johnson & Johnson | 11 | $355 |
| AstraZeneca | 12 | $234 |
| GSK | 13 | $227 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $215 |
| Bayer | 11 | $197 |
| Lilly USA, LLC | 9 | $146 |
| Amgen | 9 | $140 |
| Boehringer Ingelheim | 7 | $139 |
| Merck | 7 | $113 |
| Sanofi-aventis U.S. LLC | 5 | $89 |
| Exact Sciences | 4 | $81 |
| Esperion Therapeutics, Inc. | 2 | $78 |
| Amarin Pharma, Inc. | 4 | $76 |
| Astellas Pharma US Inc | 4 | $76 |
| Otsuka America Pharmaceutical, Inc. | 4 | $73 |
| Phathom Pharmaceuticals, Inc. | 2 | $51 |
| Novartis | 3 | $45 |
| Eisai Inc. | 2 | $44 |
| Lundbeck LLC | 2 | $39 |
| Inogen, Inc. | 3 | $38 |
| Neurocrine Biosciences, Inc. | 2 | $35 |
| Nestle Healthcare Nutrition Inc. | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Corium, LLC | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Boston Scientific | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,325 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 52 | $82,032 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 95 | $80,787 |
| EliquisApixaban | 75 | $73,845 |
| VraylarCariprazine Hcl | 35 | $49,761 |
| XareltoRivaroxaban | 39 | $31,177 |
| MounjaroTirzepatide | 17 | $29,784 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $29,546 |
| JardianceEmpagliflozin | 16 | $20,177 |
| FarxigaDapagliflozin Propanediol | 29 | $18,969 |
| JanuviaSitagliptin Phosphate | 12 | $10,961 |
| Repatha SyringeEvolocumab | 14 | $9,948 |
| MyrbetriqMirabegron | 11 | $9,632 |
| LinzessLinaclotide | 18 | $9,177 |
| VascepaIcosapent Ethyl | 15 | $7,606 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 133 | $4,203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta | $227 | $82,971106 claims |
| Novo NordiskOzempic | $761 | $82,03252 claims |
| PfizerEliquis | $683 | $73,84575 claims |
| AbbVieVraylar, Linzess | $1,167 | $58,93853 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $234 | $48,51556 claims |
| Johnson & JohnsonXarelto | $355 | $31,17739 claims |
| Lilly USA, LLCMounjaro | $146 | $29,78417 claims |
| Boehringer IngelheimJardiance | $139 | $20,17716 claims |
| MerckJanuvia | $113 | $10,96112 claims |
| Astellas Pharma US IncMyrbetriq | $76 | $9,63211 claims |
| Sanofi-aventis U.S. LLCLantus | $89 | $2,37814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Ocala
- Kelly BowmanOcala$316K
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.